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Femoral endarteritis associated with percutaneous
suture closure: New technology, challenging
complications
H. Whitton Hollis, Jr, MD, and Thomas F. Rehring, MD, Denver, Colo
Objective: Use of percutaneous suture closure devices after catheter-based interventions is increasing. We recently have
seen several severe femoral arterial wall infections after use of such devices. The purpose of this study was to examine the
incidence, comorbid associations, and management of femoral arterial infections associated with percutaneous suture
closure devices.
Methods: We retrospectively reviewed all infectious complications that occurred after 2223 consecutive cardiac catheter-
ization procedures performed over 12 months in a university-affiliated community teaching hospital. Outcome variables
included demographics, procedural details, infection, type of arterial reconstruction required, mortality, and limb loss.
Results: During this study, 822 patients received percutaneous suture devices. Infection developed in 6 patients (0.7%).
The incidence of diabetes in the population undergoing percutaneous suture closure was 219 of 822 patients (26.6%).
Three comorbid conditions, noted in multiple patients with infectious complications, included diabetes mellitus, obesity,
and placement of a percutaneous suture closure device within the past 6 months. Invasive femoral endarteritis developed
in 4 patients. Gram-positive cocci predominated in 4 patients. In 1 patient with polymicrobial infection catastrophic
complications developed, including multiple anastomotic ruptures and hemorrhage. A new method of repair that
incorporated double-thickness everted saphenous vein was used in 2 patients, and safe arterial closure was achieved. There
was 1 late fatality on postoperative day 36. Limb salvage was achieved in all patients.
Conclusions: Femoral endarteritis complicating percutaneous suture closure is a challenging new problem for vascular
surgeons and can result in catastrophic complications. Customary techniques that use saphenous vein patch or
interposition grafting are not adequate in all circumstances. Successful outcome requires operative exploration in patients
with suspected infection. Removal of the percutaneous suture closure device and debridement to normal arterial wall is
recommended in all patients with suspected femoral endarteritis, based on positive intraoperative Gram stains or
abnormal appearance of the adjacent femoral artery. Early success with an autologous bolstered repair is reported.
Caution is advised when considering the use of a percutaneous suture closure device in patients with comorbid conditions
including diabetes, obesity, and previously implanted devices. (J Vasc Surg 2003;38:83-7.)
Percutaneous suture closure devices (PSCD) were de-
signed to limit manual compression, increase early ambu-
lation, and decrease the incidence of hematoma and pseu-
doaneurysm formation after catheter-based interventions
in the arterial circulation.1-3 The larger access port punc-
ture sites required for major interventions can be success-
fully closed with these devices. Initial reports of PSCD
safety profiles suggested few major complications associ-
ated with their use.4 While significant limb-threatening
arterial injuries have been reported, only scattered reports
of infectious complications have been published in the
literature.5-8 We noted a substantial increase in the number
of arterial wall infections at our institution that appeared
directly related to use of a popular PSCD. To determine the
incidence of infection and clarify management options as-
sociated with complications resulting from use of such
devices, we reviewed all infectious complications that de-
veloped after use of a PSCD after coronary catheterization
during a consecutive 12-month period at our teaching
hospital.
METHODS
A review of all infectious complications that developed
after cardiac catheterization was performed between Octo-
ber 1, 2000, and September 31, 2001. During this period,
2223 consecutive cardiac catheterizations in 2119 patients
were performed at our institution. Analyzed variables in-
cluded patient demographics, incidence of infection, bac-
teria isolated, nature and type of arterial reconstruction
required, mortality, and limb loss.
RESULTS
During the study period, 822 patients received a
PSCD. In this group, 219 patients (26.6%) had diabetes. In
the group of patients undergoing only diagnostic cardiac
catheterization, 479 of 1597 (30%) puncture sites were
closed with a PSCD, compared with 343 of 522 (65.7%)
puncture sites in patients undergoing percutaneous cardiac
interventions. Infectious complications occurred in 6 pa-
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tients (0.7%) in whom PSCDs were used. Four of these
patients had diabetes. Symptoms at presentation, demo-
graphic data, and pertinent comorbid conditions for all
patients in whom an infectious complication developed are
shown in Table I. One third of patients (2 of 6) had soft
tissue infections limited to the skin or subcutaneous tissue,
and most patients (4 of 6) had invasive femoral endarteritis.
Operative findings, method of repair, and outcome in each
of the 6 patients is shown in Table II. The transmural
inflammatory response typical of femoral endarteritis is
shown in Fig 1. Gram-positive isolates predominated in 4
patients, and polymicrobial isolates were present in 2 pa-
tients. Pathogens associated with invasive femoral endarte-
ritis in this series are listed in Table III. No infection was
successfully managed with antibiotic therapy alone. All
patients required operative intervention to control sepsis.
Specimens of the arterial wall and surrounding tissues were
taken in all patients, and cultures were positive in 5 of 6
patients. One patient manifested a clinically infected lym-
phocele 1 week after repair of a noninfectious complication
of PSCD use, and had received systemic antibiotic therapy
before operative exploration of the wound. Intraoperative
cultures were negative. In all patients with invasive femoral
endarteritis the infection was treated with arterial wall
resection to normal vessel, vein patch closure, or arterial
resection with interposition grafting, plus postoperative
antibiotic therapy for 6 weeks. Full recovery was achieved in
5 patients. No amputations were required. The only post-
operative death occurred in a patient who had respiratory
failure and end-stage renal disease before cardiac catheter-
ization. At the request of the family, dialysis was discontin-
ued, and the patient died on postoperative day 36, with
open groin wounds.
Illustrative case. After acute myocardial infarction, a
65-year-old white man underwent cardiac catheterization
with single-vessel angioplasty and stent placement at an
outside facility. A PSCD was placed. The patient was dis-
charged with clopidogrel and warfarin sodium therapy.
One month after catheterization the patient underwent
primary repair of a femoral false aneurysm. Prominent
lymph nodes were noted at exploration. Postoperatively,
fever developed, with temperature to 105°F and blood
Table I. Demographics and symptoms at presentation
Patient Age (y) Gender Comorbid conditions Symptoms at presentation
Isolated soft tissue infection
1 73 F Diabetes, obesity, ESRD, CAD Pain, acute arterial occlusion
2 75 F CAD only Pain, intimal dissection on
angiogram
Invasive femoral endarteritis
3 67 M CAD only Pain, pseudoaneurysm
4 72 M Diabetes, obesity, CAD Pain, pseudoaneurysm, sepsis
5 74 M Diabetes, CAD Pain, infected groin hematoma,
sepsis
6 48 M Diabetes, obesity, CAD Pain infected groin hematoma, sepsis
ESRD, End-stage renal disease; CAD, coronary artery disease.
Table II. Operative findings, type of reconstruction, and outcomes
Patient Operative findings Reconstruction Outcome
1 Initial operation because of arterial
occlusion; no infection;
inadequate arterial inflow
PSCD removed; femoral-femoral
bypass with ePTFE graft
Soft tissue infection required opening of
wound; graft exposed; dialysis
withdrawn; death (postoperative day
36)
2 Initial operation because of severe
stenosis after intimal dissection;
no infection
PSCD removed; ePTFE patch;
angioplasty
Erythema, pain, fluctance, infected
lymphocele; wound opened; delayed
healing; recovered
3 Initial operation because of
pseudoaneurysm; multiple
subsequent operations (see text
for details)
PSCD removed; primary repair;
saphenous vein interposition
failure; superficial femoral vein
interposition failure;
hemorrhage, axillo-popliteal
bypass grafting
Multiple hemorrhages, anastomotic
disruptions; delayed healing;
prolonged hospitalization;
gastrointestinal bleed; nonfatal
cardiac arrest; recovered
4 Infected pseudoaneurysm, groin
hematoma, staphylococcal sepsis
PSCD removed; ePTFE patch Delayed wound healing; recovered
5 Infected pseudoaneurysm,
staphylococcal sepsis
PSCD removed; BEST procedure Delayed wound healing; recovered
6 Infected pseudoaneurysm,
staphylococcal sepsis
PSCD removed; BEST procedure Delayed primary closure; recovered
PSCD, Percutaneous suture closure device; ePTFE, expanded polytetraflouorethylene; BEST, bolstered, everted, saphenous vein technique (see text for details).
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cultures positive for methicillin-sensitive Staphylococcus
aureus. The patient was returned to the operating room,
where an infected hematoma was incised and drained.
Spontaneous hemorrhage from the wound on the third
postoperative day ensued, prompting a second attempt at
primary repair. Recurrent hemorrhage necessitated repeat
exploration, resection of the common femoral artery, and
interposition grafting with superficial femoral vein. Hem-
orrhage followed. The vein graft was removed. Histologic
analysis was consistent with acute inflammation and entero-
cocci (Fig 1, B). Final cultures grew methicillin-resistant S
aureus, enterococci, staphylococci (non–S aureus), and
Bacteroides species. Total hospitalization exceeded 10
weeks, with axillo-popliteal bypass grafting ultimately re-
quired for limb salvage.
Surgical technique. We have noted early success with
repair with the bolstered, everted, saphenous vein patch
technique (BEST procedure; Fig 2). Broad-spectrum anti-
biotics are administered in the preoperative area, and the
patient is given general anesthesia. The operative field
should include a site for harvesting at least 5 cm of autolo-
gous greater saphenous vein. Use of ipsilateral groin greater
saphenous vein may be hampered by extensive local indu-
ration, and alternate sites should be included in the sterile
field. Arterial control of the common femoral artery should,
ideally, be achieved proximal to the area of contamination.
Fig 1. A, Histologic section of infected femoral artery. Note dense transmural inflammatory reaction (hematoxylin-
eosin; original magnification, 200). B, Acute inflammation of endothelium with macrophages and enterococci
(hematoxylin-eosin; original magnification, 400).
Table III. Bacterial isolates
Patient Organisms cultured
1 Escherichia coli, Staphylococcus aureus, -hemolytic
streptococcal species, Corynebacterium species,
Klebsiella species
2 No growth; patient given antibiotic therapy 1
week before operation.
3 Staphylococcus aureus, Staphylococcus epidermidis,
Enterococcus species, Bacteroides species
4 Staphylococcus aureus, Corynebacterium species
5 Staphylococcus aureus
6 Staphylococcus aureus
Fig 2. Schematic representations of preferred closure using a
bolstered, everted, saphenous vein patch technique (BEST proce-
dure).
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Cultures of the fluid and arterial wall must be obtained to
direct future antibiotic therapy. A Gram stain of the in-
volved tissues is obtained. Systemic heparin is administered
after vascular control is achieved. If the PSCD has not
spontaneously extruded with these maneuvers, all foreign
material is then removed from the arterial wall. The femoral
artery is sharply debrided to normal arterial wall, and the
resultant defect is evaluated. If the defect is small (3-4
mm), ankle vein is suitable for closure. Larger defects (4
mm) require groin vein for adequate size matching. A
minimum of 5 cm of vein should be harvested. The vein is
then everted as a double-thickness patch. This portion of
the everted vein must be large enough to prevent stenosis
after closure of the common femoral artery. The remaining
vein segment is used as a continuous autologous pledget.
The patch is anchored in place at the proximal and distal
ends with fine prolene sutures in a mattress configuration.
Once the patch with its bolster is secured proximally and
distally, running closure is easily accomplished (Fig 2). One
layer of subcutaneous tissue is closed to protect the artery,
leaving the remaining subcutaneous tissue and skin open. We
prefer to use vancomycin-tobramycin–impregnated methyl-
methacrylate beads placed in the superficial layer of the
wound initially and removed at day 5, when delayed pri-
mary closure can generally be accomplished. It has been our
custom to administer a full 6-week course of antibiotic
therapy tailored to culture and sensitivity results.
DISCUSSION
Use of percutaneous suture closure devices is increas-
ing.9,10 Recently such devices have been used to close
defects associated with cardiac catheterization, central ve-
nous catheterization, and percutaneous cardiac interven-
tions.3 An increase in the number of reported complica-
tions parallels the increased use of PSCDs by cardiologists
worldwide. In a comparison of two popular products, with
manual compression as a control group, Duffin et al11
reported an increase in complications associated with the
Perclose device (Perclose, Redwood City, Calif). In a pro-
spective study of 1500 patients they noted a statistically
significant increase in the number of noninfectious access
site complications, including hematoma, pain, and bleed-
ing, with the Perclose device as compared with the Angio-
Seal device (St Jude Medical, Minnetonka, Minn) or man-
ual compression. Sprouse et al5 reported three infections
among 11 complications of percutaneous suture closure,
and noted the devastating nature of such infections.
We are not aware of any previous studies in the surgical
literature that document the incidence of infectious com-
plications of PSCD use; only isolated case reports exist.
Tolerico6 reported a single case of femoral endarteritis, and
suggested that antibiotic therapy alone may be effective.
However, we submit that long lengths of braided suture
material in the subcutaneous tissue may contribute to de-
velopment of invasive femoral endarteritis, which is unlikely
to resolve with antibiotic therapy alone. Of most concern
was a sudden increase in the incidence of invasive femoral
endarteritis, a heretofore unknown problem at our institu-
tion. This study confirms the manufacturer’s assertion that
the risk for infection is small12,13; however, development of
femoral endarteritis after use of PSCDs can result in devas-
tating complications.14 In their brief report, Johanning et
al7 reviewed the Manufacturer and User Facility Device
Experience (MAUDE) for suture closure devices. At the
time of their report, 20 infectious complications had been
reported to the MAUDE database. As of this writing, the
MAUDE database contains reports of 25 infectious com-
plications, of 131 incidents. One submission cites multiple
infections on a single incident report. Our experience re-
flects only complications secondary to the Perclose device;
however, others have reported similar infectious problems
with other closure devices.14
In this series, two types of infectious complications
developed: isolated soft tissue infection and invasive femo-
ral endarteritis. Two patients had isolated soft tissue infec-
tions that developed several days after removal of the PSCD
and repair of the arterial injury (Table II). In 1 of these
patients a soft tissue infection exposed the femoral-femoral
crossover graft used to repair the damaged femoral artery.
The other patient underwent repeat exploration of the
wound, which was left open, without resultant infection of
the expanded polytetraflouroethylene patch used to repair
the dissection. Invasive femoral endarteritis developed in all
4 remaining patients. The methods of treatment and out-
come are noted in Table III.
The distinction between femoral endarteritis and iso-
lated soft tissue infection cannot be made with physical
examination of the groin alone. In this initial experience,
isolated groin infections developed only subsequent to
removal of a PSCD because of noninfectious complica-
tions. We believe that all patients with symptoms at presen-
tation that include pain, fever, erythema, or frank sepsis
after receiving a PSCD should undergo exploratory surgery
immediately. At exploration, all foreign material should be
removed, and Gram stains of the tissue fluid, hematoma,
and arterial wall should be obtained. If the Gram stain is
positive or if the arterial wall has clearly abnormal appear-
ance or texture, we suggest the arterial wall be debrided to
macroscopically normal tissue. Cultures should be taken of
the arterial wall, and if they are positive, long-term antibi-
otic therapy tailored to sensitivity is warranted. In our
experience, with lesser operations in which the device is
simply removed and the artery primarily closed there is risk
for inadequate treatment of any invasive femoral endarteri-
tis that may be present. In contrast to other reports,7our
experience is that simple autologous vein patch closure
cannot be relied on for successful repair. Any invasive
femoral endarteritis may result in autologous vein patch
disruption, with life-threatening or limb-threatening hem-
orrhage as a result. Troubled by our lack of success with
simple saphenous vein patching in patient 3, we began to
use the previously unreported BEST procedure, with a
bolstered, everted, double thickness saphenous vein patch.
While the superiority of a bolstered repair over conven-
tional vein patch remains unproved, our early experience
supports its use. We have not experienced autologous patch
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disruption in the 2 patients in whom the BEST procedure
was used. Vascular surgeons are experienced with bolstered
anastomoses in endarterectomized aortic segments. This
experience leads us to favor bolstered suture technique
anytime the arterial wall may appear compromised. We
believe that invasive femoral endarteritis puts the patient at
risk for primary repair failure and subsequent anastomotic
or patch disruption. Nonetheless, the gravity of the poten-
tial consequences mandates a conservative approach to
these problems. We offer the BEST procedure as an alter-
native approach, recognizing that this is a new technique
that will require validation in direct comparison with the
conventional saphenous vein patch. Our suspicion that
infection adds to the risk of patch or anastomotic disruption
is supported by outcomes in Case 3. Without clear evidence
proving conventional vein patch superiority, bolstered re-
pair seems prudent when invasive femoral endarteritis is
suspected intraoperatively.
CONCLUSIONS
This is the first incidence study of infectious complica-
tions after use of a PSCD reported in the surgical literature.
In this review of 2223 consecutive cardiac catheterization
procedures, 6 patients receiving one or more PSCDs devel-
oped infectious complications. Comorbid conditions in 4
of 6 patients in whom invasive femoral endarteritis devel-
oped included diabetes and obesity. Although the inci-
dence of infection is 0.7% in our series, these cases represent
major reconstructive challenges with significant and poten-
tially fatal consequences.10 Double-thickness everted sa-
phenous vein patching may be a useful adjunct in treatment
of such cases. Since implementing restrictions to deploy-
ment of the Perclose device in the subset of patients with
obesity, diabetes, or a PSCD previously placed within 6
months, we have noted only 1 additional case of invasive
femoral endarteritis at our institution. In this group of
patients, manual compression or use of other available
devices is preferred, to prevent direct arterial contamination
by sutures penetrating the full thickness of the arterial wall.
Multicenter trials will be required to confirm our initial
suspicion that diabetes, obesity, and multiple device de-
ployment are risk factors for development of septic compli-
cations after percutaneous suture closure. We recommend
caution when deploying such devices in patients with these
risk factors.
We thank Molly Borman-Babich, medical illustrator,
for her assistance with the schematics in Fig 2.
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